The myoneural junction, or site where the motor nerve ending meets the muscle fibre, consists of : 1) The Motor Nerve Ending which arborizes close to the muscle into as many as 1,000 branchlets, each ending in a terminal bud ( Fig. 1 ) which contains energy-supplying mitochondria and vesicles filled with bound, inactive acetylcholine (ACh) (6) ( The MEP is bathed on the outside by a fluid containing excess of Na-]-and in the inside by a fluid containing an excess of K+. In the resting muscle cell there is a negative potential of 70 mV across FIGURE 1.
Schematic Sketch Illustrating Motor Nerve Endings of a Muscle Fascicle
By kind permission of J. Eccles and Sci. Amer., Jan. 1965 (modified) .
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the MEP, or between the inside and outside of the cell. This negative potential is due to the difference in ionic potential between the Na-]-lying outside of the membrane and the K+ in the inside. When it is in this state the MEP is said to be polarized: There is no ionic movement, no current, and no muscle contraction.
Muscle contraction is initiated by the nerve impulse as follows: the nerve impulse activates and releases the ACh in the bud vesicles into the Sc. Here the ACh diffuses in less than 0.1 microsecond over the entire MEP. In the MEP the ACh unites with receptor protein to form ACh-receptor complex (Fig. 3 ). This complex alters the permeability of the MEP allowing Na-]-to flow into the cell, and to a lesser extent K+ to flow out ( Fig. 4 ). This ionic shift reduces the negative potential across the MEP. When the potential across the MEP reaches +12 mV it gives rise to an MEP spike that initiates a propagated action potential in the muscle cell which spreads throughout its length. This potential activates the actin-myosin-ATP reaction which causes the cell to contract (15) . The process of reducing the negativity inside the muscle cell is called depolarization.
Once the MEP is fully depolarized current flow and muscle contraction ceases. If depolarization persists, the muscle becomes relaxed. Under normal conditions depolarization, which occurs within one millisecond, does not persist because acetylcholinesterase (AChE) present in the MEP inactivates the ACh allowing the MEP to repolarize. The next nerve impulse releases more ACh and starts the entire process over again.
Neuromuscular transmission (NT) can be interfered with at any point of the path mentioned. Therefore it is obvious that apnea can be caused by many factors. Vol. 11, 1966 For In patients with prolonged apnea it is important to recognize which type of block is causing the apnea. This can be done by means of the differential characteristics of polarizing and depolarizing agents. These show the following features:
Polarizing agents: H the patient shows post-tetanic potentiation with single stimuli and his apnea is relieved by prostigmin, a polarizing block is present. If there is no post-tetanic potentiation and the block is not relieved by prostigmin, a depolarizing block is present. Post-tetanic potentiation can be easily elicited by first applying to the thenar eminence of the hand a tetanic current until the muscle becomes unresponsive and then applying single electric stimuli. If the muscle responds to the single stimuli with strong twitches, potentiation is present
Chemistry of NM Transmission and SCh Action
The following formulas demonstrate some relationships among acetic acid, choline, acetylcholine, SCh and the specific enzyme butyrylcholinesterase (BChE), all of which are concerned with NMT and NM block. Acetic acid plus the alcohol derivative choline forms acetylcholine. I  I  I  I II  I  I I: , (19) . However, it is undoubtedly of importance in patients with either low or abse~t BChE. L,ess than 10% of injected SCh IS excreted m the urine unchanged.
On intravenous injection, SCh is hy-drolY,zed on contact with plasma butyrylcho Iin est e r ase (BChE) (also called pseu?o-cholinesterase) to succinylmono-hol~ne and. choline. Succinylmonocholine in turn IS hydrolyzed by the specific enzyme succinylmonocholinesterase into succinic acid and choline.
All choline compounds have some blocking action, but the blocking actions of succinylmonocholine and choline are so weak that for practical purposes they may be considered negligible. Although most of the SCh is quickly hydrolyzed in the. plasma, a small portion escapes the action of the enzyme and reaches the MEP. Here SCh is insulated from the act~on of BChE, and exerts its blocking action bf .pe~sistent~y depolarizing the MEP until It diffuses into the perivascular spaces (14) .
The duration of the clinical effects of SCh depends on the amount of SCh that reaches the MEP. This in turn depends on a number of factors such as: 1) the titer of plasma BChE, 2) the absence of BChE, 3) the dose of SCh, 4) freshness (potency) of the SCh solution, 5) the r~te o.f its administration, 6) the circulanon tIm~of the patient, 7) the presence of barbiturates or other drugs in the plasma, and 8) the particular technique of electroshock therapy used. For lack of°F rom studies performed at Burroughs-Wellcome Laboratories.
spac~only the amount of BChE present and Its complete absence are discussed.
The Concentration (Titer) of HChE in the Plasma BChE is synthesized in the liver. Plasma BChE concentration is below normal in liver diseases, severe anemias, cancer malnutrition, as well as in persons expo~ed to the action of anticholinesterases such as nerve gases and weed killers. The lower the titer of BChE the greater will be the paralytic and ap.neic effect of a given dose of SCh. Patients suffering from the above diseases causing low BChE levels react with prolonged apnea to the usual therape~tic .dos~of. SCh. (20-30 mg). BChE titer I~high in patients suffering f!'om nephrosis (14) . These patients show little muscular relaxation to the usual therapeu~ic dose of SCh and are subject to potentially dangerous convulsions. The concentration of BChE in blood plasma varies from below 100 to above 300 Goldenberg units. The normal range is 150-250 units.
. The rate of hydrolysis of SCh is directly dependent on the concentration of the BChE (14) so that higher titers of the en~yme cause faster hydrolysis of SCh WIth less SCh reaching the SM. Patients with low levels of BChE hydrolyze SCh slowly. This allows more SCh to reach the MEP which in turn prolongs the duration of the block.
A patient with normal titer of BChE is capable of hydrolyzing 40 mg of SCh per m~nute . (14) . Apne~longer than one minute m such a patient cannot possibly be due to any SCh present in the plasma, for by the end of the minute all of the SCh in the plasma has been hydrolyzed. The apnea is due to the small 'amount of SCh that escapes hydrolysis in the plasma and reaches the MEP unchanged. Since the SCh in the MEP is in effect insulated fro~the action of BChE, it is practically futile to attempt to alleviate prolonged apnea by raising the titer of BChE in the plasma by transfusion or other means. The ineffectiveness of a transfusion in such situations is questioned by some observers (4).
Congenital Absence of Plasma BehE
BChE is completely absent from the plasma in about one out of 3,000 patients. This frequency has been genetically determined (14) . Most patients inherit only partial lack of BChE. The general population may be divided into four larger groups: 1) Patients who have a full complement, or abnormally high titers, of BChE, who react poorly to SCh and need larger doses of SCh for adequate relaxation. 2) Patients who have a partial lack, or normal titer, of BChE, who react adequately to the usual therapeutic dose.
3) Patients who have substantial lack, or low titer, of BChE but respond adequately to small doses of SCh. 4) Patients who completely lack BChE who respond with complete paralysis and prolonged apnea to even small doses of SCh.
These four groups are illustrated in Figure 5 . Please notice that 100 mg of SCh produces an apnea lasting 60 minutes in the patient with absent BChE, 13 minutes in the patient with low BChE titer, 6 minutes in the patient with normal BChE, and only 2 liz minutes in the patient with high BChE level. A dose of 1,000 mg of SCh caused apneas lasting 14 minutes in the patient with high BChE and 25 minutes in the patient with normal BChE. In contrast in the patient with total absence of BChE, 100 mg of SCh caused an apnea lasting 60 minutes, with a steep, almost perpendicular rising curve, while in the patient with low BChE, 500 mg of SCh caused an apnea of 30 minutes, with a less steeply rising curve.
These findings clearly indicate the close relationship between the amount of BChE and the duration of apnea. These observations also point out the advisability of keeping the SCh dosage very low in patients with either very low or completely absent BChE. In such patients even a small dose, such as 5 mg, of SCh may cause apnea of 10 minutes or more. The usual therapeutic dose of 20 mg may cause apnea for over 40 minutes. Although in CT apnea may be due to other causes, in most patients it is due to a low or a complete absence of BChE (14) .
Relationships Among BChE Titer, a Small Dose of SCh and the Degree of Relaxation in Patients Receiving CT
The main problem in the admini~tra tion of SCh in CT is to detect patIents with absent or low cholinesterase so as to avoid potentially dangerous apneas. It has been suggested that this could be done by estimating the titer of BChE esterase present in the plasma, and basing the dose of SCh to be given on the value of the titer found (14) .
During the past year and a half, we, at Kings Park State Hospital, have dete~ mined the titers of BChE in blood specImens taken from a good number of patients during the course of electroconvulsive treatments.* We undertook these studies to ascertain whether there was any direct relationship between the titer BChE and the degree of muscle relaxation produced by a constant small dose of SCh. In our experiments, we first procured a control blood specimen, then gave the patients 15 mg of SCh, and within 45 seconds produced the convulsion. One minute later we obtained a second specimen of blood, an hour later a third blood sample. We found no consistent difference in the titers of the enzyme from the blood specimens taken before the convulsion, immediately after, and an hour later. There was also no direct relationship between the BChE titer and the amount of relaxation observed with the use of 15 mg of SCh. However, there is a relationship when doses of SCh of 50 mg or higher are used (14) . The BChE titer is therefore of OWe wish to thank Dr. William P. Colvin and Burroughs-Wellcome and Co. for a grant-in-aid in support of this work. little help when small doses of SCh are to be used. In this study we did not have a single patient with absent BChE.
The 3 mg Test Dose
To detect the presence of low or absent BChE we have suggested a physiologic test which is more practical and more reliable than the estimation of the esterase titer. This is the 3 mg test dose which is performed as follows: Three mg of SCh is given intravenously and the patient is observed for a full minute for signs of apnea, paralysis and the abolition of the knee jerk. If these signs occur the patient has either no BChE or a very low BChE. At this time the patient may be given the GM as he will have good muscle relaxation and a brief apnea of only 2-3 minutes. If the patient shows little or no reaction to the 3 mg test dose it indicates that he has either a normal or elevated BChE titer.
Another problem with the use of SCh is the occurrence of severe convulsions with adequate doses (25-50 mg) of SCh. One patient who had received 80 mg SCh by intravenous drip had a violent convulsion and suffered an injury to a humeral cuff. Such patients have a high BChE titer. With these patients the assaying of the BChE titer also seems to be a good solution for estimating the dose of SCh they need for adequate relaxation. However, there are other causes besides a high BChE titer for insufficient relaxation with seemingly adequate doses of SCh. These are: 1) miscalculation of the therapeutic dose of SCh, 2) technical failure to administer the full dose of SCh, 3) administration of a solution of SCh of diminished strength, 4) too slow a rate of injection of SCh, and 5) when the convulsive treatment is given before adequate relaxation has occurred.
Since the titer of the BChE is unrelated to any of these factors the use of the BChE titer as a guide for the indicated amount of SCh is not fully reliable. What is needed is a test which will take all factors, including a high BChE, into account. Such a test is the tendon reflex test.
Tests Used to Estimate the Proper Dose of SCh Presently KGT. is being administered either by psychiatrists alone or assisted by anesthetists. When done by the psychiatrist alone, he estimates the amount of SCh based on the size and muscularity of the patient. This method is entirely unreliable since there exists natural variations in the BChE titers among different patients. When an anesthetist administers SCh, he not only makes a preliminary estimation of the dose of SCh by the size and muscularity of the patient, but also is guided by two tests to help determine when there is sufficient relaxation before the convulsion. These are the masseter muscle relaxation and the pulmonary resistance tests.
The masseter muscle relaxation test is performed by simply depressing and elevating the lower jaw to get the feel of the amount of relaxation in this muscle. When the anesthetist feels that the masseter is fully relaxed he notifies the psychiatrist to invoke the convulsion.
The pulmonary resistance test depends on the production by SCh of progressive weakness of the intercostal muscles and diaphragm. The patient is first anesthetized with an ultra-short-acting barbiturate. This is at once followed by an intravenous drip of SCh 0.02% (2 mg per cc). The anesthetist immediately begins to respirate the patient with oxygen by rhythmically squeezing the breathing bag. Normally, the lungs supported by the respiratory muscles offer a certain amount of resistance to the rhythmic squeezing of the breathing bag. As the effect of the SCh increases intercostal muscles and diaphragm become weaker and weaker and the lung resistance becomes less and less. When the resistance is completely absent the patient is ready for the convulsion.
These two tests are not absolutely reliable because now and then, when the anesthetist considers the patient to be fully relaxed, a potentially dangerous strong convulsion ensues.
The 5 mg SCh Test
To gauge the amount of SCh a patient might need for adequate relaxation we formerly advocated the 5 mg SCh test dose (12) . This test was based on the percentage loss of strength of the hand grip from 30-45 seconds after an intravenous injection of SCh. The amount of SCh needed for adequate relaxation was calculated from the relative weakness of the handgrip produced by the 5 mg test dose of SCh. This test has proved inadequate because 1) it did not take into account all the factors mentioned above, 2) the test was disagreeable to some of the patients since no prior anesthesia was given and, 3) on rare occasions this 5 mg dose of SCh caused serious apneas lasting 10 minutes or longer (16) .
The Tendon Reflex Test
Several years ago we developed the tendon reflex test following the failure of the pulmonary resistance test and the consequent humeral cuff injury in the patient mentioned above (13) . The tendon reflex test is based on the theory that since SCh acts peripherally, at the motor end plate, abolition of a tendon reflex is due to paralysis of the muscle activating that particular reflex. Thus, abolition of the knee jerk would point to the paralysis of the quadriceps muscle. In addition, since we know that SCh causes a descending paralysis, the abolition of the knee jerk would indicate that all the muscles above the quadriceps were also paralyzed. This theory was proved as time and time again, we obtained, with mathematic certainty, a 3 or 4 plus" muscular relaxation when the knee jerk had been abolished. In a further study we ob- served that if the ankle jerk was abolished a 4 plus relaxation was consistently achieved (13) .
The tendon reflex test has been of great help whenever complete relaxation was imperative. Such a situation arose at Creedmoor State Hospital in a patient who had two recent fractures and could receive E.C.T. only if his convulsions were induced under complete relaxation. A five cc syringe was filled with 5Ch (100 mg). We anesthetized him and began the injection of 5Ch. He was not sensitive to the 3 mg test dose. The knee jerk was still present after 60 mg of 5Ch was administered. The knee jerk disappeared after 80 mg. The ankle jerk was abolished after he had received a total of 100 mg of 5Ch. The convulsion induced at that time was completely relaxed as not a muscle moved, except at the end of the convulsion when mild foot and toe movements were present. Following the convulsion there was a brief apnea of one or two minutes. This patient subsequently had 11 other treatments, each time receiving 100 mg of 5Ch, and each time having a fully relaxed convulsion with practically no apnea. In his case the ankle jerk test proved to be a simple way of forecasting the need of 100 mg of 5Ch .for full relaxation.
The tendon reflex test is easy to perform. If the patient shows no reaction to the 3 mg 5Ch test dose, he has neither absent BChE nor a very low titer of BChE. He is then given 10-15 mg of 5Ch, and in twenty seconds the knee jerk is elicited, preferably with a percussion hammer. If there is a reflex response the tapping is repeated every five seconds until the jerk is abolished. If the knee jerk is still present after a full minute, 10 mg more of 5Ch is injected and the procedure repeated. Once the knee jerk is abolished, the patient is ready to receive the convulsive stimulus. By using this test one actually titrates the dose of 5Ch needed to yield a 3 or 4 plus relaxation. This makes entirely unnecessary guessing the therapeutic dose of 5Ch such as is the case in using the size and weight of the patient, or by any other method. The tendon reflex test, by removing the guesswork in 5Ch administration places it on a scientific basis.
When administering 5Ch one should attempt to detect patients with absent BChE, as well as patients with low or high titers of BChE. The 3 mg 5Ch test dose helps to detect those rare patients who lack BChE. The knee and ankle tendon reflex tests help to detect patients with low or high titers of BChE.
Summary and Conclusions
Familiarity with certain physiologic and biochemical reactions and factors of succinylcholine (5Ch) in man is helpful in safely administering 5Ch in convulsive therapy and anesthesiology. These reactions and factors are: 1) the natural variations in the titer of butyrylcholinesterase (BChE) in the plasma, 2) the interactions between 5Ch with BChE, 3) the action of 5Ch in the congenital absence of BChE, 4) understanding of the mechanism of transmission of the nerve impulse, 5) the action of succinylcholine at the motor end plate. Discussion of the above reactions and factors are presented. Two physiologic tests are described. These are the 3 mg 5Ch test dose and the tendon reflex test. The proper application of these two tests make possible the safest use of succinylcholine in convulsive therapy, as well as in other fields of medicine.
